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Abstract
Surgical extent-of-resection has been shown to have an impact on high-grade
glioma (HGG) outcomes; however, complete resection is rarely achievable in
difficult-to-access (DTA) tumors. Controlled thermal damage to the tumor may
have the same impact in DTA-HGGs. We report our multicenter results of laser
interstitial thermal therapy (LITT) in DTA-HGGs. We retrospectively reviewed
34 consecutive DTA-HGG patients (24 glioblastoma, 10 anaplastic) who underwent LITT at Cleveland Clinic, Washington University, and Wake Forest University (May 2011–December 2012) using the NeuroBlate System. The extent
of thermal damage was determined using thermal damage threshold (TDT)
lines: yellow TDT line (43°C for 2 min) and blue TDT line (43°C for 10 min).
Volumetric analysis was performed to determine the extent-of-coverage of
tumor volume by TDT lines. Patient outcomes were evaluated statistically. LITT
was delivered as upfront in 19 and delivered as salvage in 16 cases. After
7.2 months of follow-up, 71% of cases demonstrated progression and 34%
died. The median overall survival (OS) for the cohort was not reached; however, the 1-year estimate of OS was 68  9%. Median progression-free survival
(PFS) was 5.1 months. Thirteen cases who met the following two criteria—(1)
<0.05 cm3 tumor volume not covered by the yellow TDT line and (2) <1.5 cm3
additional tumor volume not covered by the blue TDT line—had better PFS
than the other 21 cases (9.7 vs. 4.6 months; P = 0.02). LITT can be used effectively for treatment of DTA-HGGs. More complete coverage of tumor by TDT
lines improves PFS which can be translated as the extent of resection concept
for surgery.

Introduction
Treatment of high-grade glioma (HGG) remains a challenge [1]. Because of their diffuse nature and infiltration
into the surrounding normal brain tissue, complete elimination of tumor cells is not achievable by the use of focal

treatment modalities like surgery [2]. Resultantly, postoperative treatments such as radiation therapy, and chemotherapy, are indicated in most cases after surgery [3–5].
Despite this, a growing body of evidence has shown that
aggressive surgical treatment as an upfront cytoreductive
procedure has an impact on outcomes for high-grade

ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of
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glioma patients [6–10]. Without initial cytoreductive
treatment, radiation and chemotherapy have more limited
efficacy [11, 12]. Unfortunately, in difficult-to-access
(DTA) tumors, aggressive surgical resection is often not
feasible [13]. Additionally, with regard to recurrent malignant glioma, the efficacy of available treatment options is
limited [14, 15]. Hence, a need for a new cytoreductive
treatment modality exists.
Laser-induced hyperthermia bears merit for consideration as a cytoreductive treatment option. In 1983, Bown
[16] showed that for lasers with greater tissue penetration
(e.g., Nd-YAG) a wider range of therapeutic effects are
seen due to tissue hyperthermia. Subsequently laserinduced thermal therapy was used as treatment for multiple different brain pathologies [17–19]. Despite early
enthusiasm for this technology, this treatment modality
failed to be widely accepted as a therapy for glioma
patients, due, in part, to limitations in monitoring the
extent of thermal damage delivered during treatment [13,
20–24]. Early on, various techniques were used to define
the extent of thermal damage induced by lasing [19, 21,
25, 26]. Eventually, MR-thermography based on the temperature dependence of the proton resonance frequency
(PRF) was used to provide real-time image guidance of
the extent of thermal damage from lasing [27]. Such
advances in technology are responsible for the resurgence
in laser interstitial thermal therapy (LITT) in recent years
[13, 28]. The NeuroBlate System (Monteris Medical
Corporation, Plymouth, MN) is one of the first LITT
devices developed in the modern MR-thermography era.
After a successful first in humans study [13], FDA 510k
clearance (K081509) was received in May 2009 without
any specific limitations for intracranial use.
In this study, we report our multicenter series of LITT
for treatment of high-grade glioma patients with the
NeuroBlate System. Volumetric analysis was performed to
evaluate the extent of thermal damage to tumor tissue
and its impact on patient outcomes.

Methods
Study design, size, and setting
This is a retrospective multicenter review of high-grade
glioma patients who were treated with the NeuroBlate
System. Thirty-four consecutive glioblastoma (GBM) and
anaplastic glioma patients who underwent a total of 35
LITT procedures from May 2011 to December 2012 at
the Cleveland Clinic (Cleveland, OH), Barnes-Jewish Hospital (Washington University, St. Louis, MO), and WakeForest Hospital (Winston-Salem, NC) were included. The
eligibility criteria included all patients who were greater
than 18 years and had pathology proven high-grade
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glioma (anaplastic glioma or GBM). One patient was
excluded from the study—he had a history of prior GBM
with multiple prior treatments including radiation therapy and his pre-LITT biopsy showed necrosis and no evidence of recurrent glioma. Patients underwent
appropriate postoperative adjuvant treatment and were
followed with serial MR imaging every 3 months. The
median patient follow-up was 7.2 months (range: 0.1–
23 months).

Data source
Multiple data sources were used for collecting the data.
Demographic data, patient characteristics, and outcomes
were collected by reviewing the patient charts after Institutional Review Board approval at each center. Volumetric
analysis of tumor coverage by thermal damage threshold
lines (TDT lines) was performed by importing the pre-,
intra-, and postoperative MRI scans as well as the TDT
lines into iPlan software (Brainlab, Munich, Germany).

Procedure
The LITT procedure was performed with the NeuroBlate
System which uses a solid state diode laser in the NdYAG range (1064 nm at 12 W). This laser energy is transferred to the target tissue via a CO2 gas-cooled side-firing
(directional) laser probe (Fig. 1). The trajectory planning
and insertion of the laser probe into the tumor were
completed through the use of surgical navigation devices
and a variety of tools specific to the NeuroBlate System.
The location of the laser probe within the tumor was
confirmed by intraoperative MRI. The lasing portion of
the treatment was planned and controlled via the NeuroBlate System computer workstation utilizing proprietary
M°VisionTM (Monteris Medical Corporation, Plymouth,
MN) software under real-time MR-thermography guidance. The real-time extent of thermal ablation is calculated by the M°Vision software based on the algorithm of
heat kill of cells (a relationship between time and temperature) and demonstrated as thermal damage threshold
(TDT) lines which include distinct yellow and blue TDT
lines. The yellow TDT line encircles the area of tissue that
has been heated to the equivalent of 43°C for at least
2 min and the blue TDT line encircles the area of tissue
that has been heated to 43°C for at least 10 min or
heated to a higher temperature for a shorter interval [13].

Variables
Progression-free survival (PFS) was chosen as the primary
end point of the study. Progression was defined as an
increase in thickness of enhancement in a previously
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Figure 1. Schematic picture of NeuroBlate System for treatment of
difficult to access brain tumors.

Figure 2. Blue and yellow TDT lines as well as tumor outline (pink)
were imported to iPlan software for volumetric analysis.

treated enhancing lesion, new enhancement, and/or an
increase in the cerebral blood volume (CBV) on MR-perfusion sequences; and PFS was measured from the date
treatment started to the date of documented progression
or death from neurological causes, whichever came first.
Secondary study end points were overall survival (OS)
and rate of surgical complications. The extent of tumor
coverage (percentage of the tumor volume encircled) by
the blue and yellow TDT lines as well as the residual
tumor volume (volume of tumor tissue not encircled) by
each of the TDT lines were measured using iPlan software
(Fig. 2) and evaluated as possible predictive factors for
PFS and OS. These results were also considered within
the context of other potential prognostic factors such as
gender, age, preoperative Karnofsky performance status
(KPS), preoperative neurological function status (NFS),
tumor pathology (anaplastic vs. GBM), type of treatment
(upfront vs. salvage), adjuvant treatment after LITT, and
tumor volume to try to adjust for possible confounding.

convenience a recursive partitioning algorithm was used
to identify cutpoints for the extent of coverage defined by
the blue and yellow TDT lines and residual volumes.
Spearman rank correlations were used to assess the relationship between tumor coverage by the blue and yellow
TDT lines and overall tumor volume. The log-rank test
and proportional hazards models were used for univariable and multivariable comparisons of PFS and OS. SAS
version 9.2 (SAS Institute Inc., Cary, NC) was used for all
data analyses.

Results
Participants
Among more than 60 patients who underwent the NeuroBlate procedure at all three medical centers during the
study period, 34 patients had the diagnosis of high-grade
glioma.

Statistical method

Descriptive data

Patient characteristics were summarized using frequency
counts and percentages for categorical factors and
medians and ranges for continuous factors. PFS and OS
were summarized using the Kaplan–Meier method. For

Median age at the time of LITT was 56 years (range: 19–
79 years) and 13 (38%) patients were female. Twenty-four
patients were diagnosed with GBM, six patients with
anaplastic astrocytoma (AA), and four patients with
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anaplastic oligodendroglioma (AO). Among 34 patients, 16
procedures (in 16 patients) were performed as upfront
treatment for newly diagnosed HGG and 19 procedures (in
18 patients) were performed for treatment of recurrent
disease. In terms of tumor location, 15 patients had tumors
located in frontal lobe, seven tumors were in the thalamic
region, five cases each had parietal and temporal lobe
tumors, two cases were insular gliomas, and there was one
corpus callosum lesion. Median preoperative (i.e.,
pre-LITT) KPS was 80 (range: 50–90). Median maximum
tumor diameter was 3 cm (range: 1.3–5.5 cm) and median
tumor volume was 10.13 cm3 (range: 0.7–49.9 cm3).
Median coverage of tumor volume by the blue TDT
line was 91% (range: 28–100%) and by the yellow TDT
line was 98% (range: 34–100%). The median residual
tumor volume (not covered) by the blue TDT line was
0.66 cm3 (range: 0–22.5 cm3) and by the yellow TDT line
was 0.19 cm3 (range: 0–15.5 cm3). LITT treatment was
performed using 1 (54%) trajectory in 19 cases, 2 (40%)
trajectories in 14 cases, and 3 (6%) trajectories in two
cases. The median estimated blood loss during surgery
was 30 cc (range: 10–100 cc), median postoperative pain
score during the first 24 h was 2/10 (data were available
in 31 patients), and median postoperative hospital stay
was 3 days (range: 1–29 days). A total of 28/35 cases
(80%) received adjuvant chemotherapy starting at a median of 3 weeks after surgery. First-line chemotherapy in all
newly diagnosed tumor patients was temozolomide. For
patients with recurrent disease a wider variety of chemotherapeutic drugs were used including temozolomide in
six cases, cytoxan in three cases, bevacizumab and lumostine each in two cases, and procarbazine in one patient.

Outcome data
Overall 71% (25/35) of cases progressed during followup. The estimated median PFS for the cohort is
5.1 months. Among the 25 cases with progression, radiographic progression was diagnosed as a result of new
enhancement in 17 cases and increased CBV on perfusion
MRI in six cases. Two additional patients died before
their first follow-up MRI without clear non-neurological
causes and were counted as progression. In the 23 cases
showing radiographic evidence of progression, five (22%)
cases had local recurrences in the central area of the treatment field, 12 (52%) cases had recurrences at the peripheral region of the treatment field, five (22%) cases had
recurrences outside the primary enhancing tumor volume
but within 2 cm of the treatment field, and one (4%)
patient had remote recurrence in the contralateral cerebral
hemisphere.
The median OS had not been reached at the time of
analysis, however, 1-year survival is estimated to be
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68  9%. Overall, 35% (12/34) of the patients have died
—progression was the cause of death in 10 patients and
two patients died because of other reasons. When evaluated in terms of pathology, 11/24 patients with GBM and
1/6 patients with AA died during the follow-up period.
None of the four AO patients died during follow-up.

Main results
Table 1 summarizes univariable analyses of PFS. We
analyzed volumetric data consisting of blue and yellow
TDT lines and overall tumor volume for each patient in
the cohort in an effort to determine if there were any
Table 1. Univariable analysis of progression-free survival.

Factor

Number of
patients (%)

Gender
Female
14 (40%)
Male
21 (60%)
Age at procedure
<60 years
19 (54%)
≥60 years
16 (46%)
Prior radiation/chemotherapy
No
17 (49%)
Yes
18 (51%)
Recurrent disease
No
16 (46%)
Yes
19 (54%)
Pathology
Anaplastic glioma
11 (31%)
Glioblastoma
24 (69%)
TDT-line coverage group
Favorable
13 (37%)
Unfavorable
22 (63%)
Location
Frontal, temporal,
25 (71%)
parietal lobe
Insula, thalamus,
10 (29%)
corpus callosum
Tumor volume
≤10 cm3
17 (49%)
>10 cm3
18 (51%)
Preoperative KPS
90
15 (43%)
80 or less
20 (57%)
Preoperative neurological function status
Asymptomatic
11 (35%)
Symptomatic
20 (65%)
Intracranial hemorrhage (any size)
No
7 (26%)
Yes
20 (74%)
Postoperative adjuvant treatment
No
6 (18%)
Radiation or chemotherapy
14 (42%)
Radiation and chemotherapy 13 (39%)

Median PFS
(months)

P-value
0.92

5.0
5.1
0.12
8.6
4.5
0.53
3.5
5.8
0.70
3.5
6.0
0.81
5.6
5.1
0.02
9.7
4.6
0.41
5.6
3.2
0.04
8.6
4.6
0.004
7.6
3.5
0.93
5.8
4.5
0.47
6.3
6.0
0.24
5.5
5.1
9.2
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characteristics of the TDT lines that were prognostic for
PFS and/or OS. Additionally, we analyzed the amount of
tumor volume that was covered by the yellow but missed
by the blue TDT line as another potential prognostic factor. Cases in which the yellow TDT line missed
<0.05 cm3 of tumor had a more favorable prognosis
(median PFS of 9.7 vs. 4.6 months, P = 0.02) as did cases
in which the coverage zone between the blue and yellow
TDT lines was <1.5 cm3 (median PFS of 7.6 vs.
3.3 months, P = 0.01). As it was impossible to determine
which TDT line is the primary prognostic factor for outcome based on the small size of our sample and the fact
that most of the patients with favorable outcomes are
common between the two groups, we decided to make a
prognostic group based on the combination of blue and
yellow TDT line. Hence two groups that were prognostic
for PFS could be defined—a favorable group and an
unfavorable group. Thirteen cases were included in the
favorable TDT line coverage group (defined as tumor volume <0.05 cm3 missed by the yellow TDT line and
<1.5 cm3 of tumor volume covered by the yellow TDT
line but uncovered by the blue TDT line) and 22 cases
were included in the unfavorable TDT line coverage
group (≥0.05 cm3 tumor volume missed by the yellow
TDT line and/or tumor volume ≥1.5 cm3 covered in the
transition zone between the yellow and blue TDT lines).
The median PFS in the favorable TDT-line coverage
group was 9.7 months compared with 4.6 months for the
unfavorable TDT-line coverage group (P = 0.02) (Fig. 3).
Multivariable models were used to assess the significance of the TDT-line coverage groups adjusting for the
possible confounding factors summarized in Table 1.
Table 2 summarizes the results of these analyses and indicates that with the exception of overall tumor volume the

Figure 3. Effect of TDT-line prognostic group on progression-free
survival.

ª 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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TDT prognostic groups remained significantly associated
with PFS even after adjusting for other factors. Overall
tumor volume is inversely correlated with tumor coverage
by the blue and yellow TDT lines as shown in Figure 4
(Spearman correlations of 0.67 and 0.66, respectively,
both P-values <0.0001). It is not surprising therefore
that controlling for tumor volume, the effect of TDT
Table 2. Effect on progression-free survival of prognostic groups
based on NeuroBlate parameters adjusted for other factors.
Hazard ratio
(95% CI)

P-value

TDT-line coverage group
(unfavorable vs. favorable)
Gender (female vs. male)

2.57 (1.12–5.92)

0.03

1.02 (0.48–2.17)

0.96

TDT-line coverage group
(unfavorable vs. favorable)
Age (≥60 vs. <60)

3.13 (1.30–7.55)

0.01

2.27 (1.02–5.04)

0.04

TDT-line coverage group
(unfavorable vs. favorable)
Prior treatment
(RT and/or chemo vs. none)

2.90 (1.22–6.90)

0.02

1.62 (0.71–3.71)

0.26

TDT-line coverage group
(unfavorable vs. favorable)
Recurrent disease (yes vs. no)

2.61 (1.13–6.00)

0.02

1.23 (0.54–2.79)

0.62

TDT-line coverage group
(unfavorable vs. favorable)
Pathology (AA/AO vs. GBM)

2.58 (1.12–5.96)

0.03

1.00 (0.45–2.26)

0.99

TDT-line coverage group
(unfavorable vs. favorable)
Location (insula, thalamus,
corpus callosum vs. lobes)

2.54 (1.06–6.07)

0.04

1.05 (0.42–2.62)

0.91

TDT-line coverage group
(unfavorable vs. favorable)
Tumor volume (>10 cm3 vs. ≤10 cm3)

2.06 (0.76–5.59)

0.16

1.48 (0.59–3.75)

0.41

TDT-line coverage group
(unfavorable vs. favorable)
Preoperative KPS (80 or less vs. 90)

2.91 (1.22–6.97)

0.02

2.30 (1.34–3.96)

0.003

TDT-line coverage group
(unfavorable vs. favorable)
Preoperative neurologic function status
(symptomatic vs. asymptomatic)

2.83 (1.17–6.86)

0.02

1.16 (0.48–2.78)

0.75

TDT-line coverage group
(unfavorable vs. favorable)
Intracranial hemorrhage (no vs. yes)

2.70 (1.00–7.28)

0.05

1.65 (0.57–4.81)

0.36

TDT-line coverage group
(unfavorable vs. favorable)
Adjuvant treatment
(none vs. RT and chemo)
Adjuvant treatment
(RT or chemo vs. RT and chemo)

3.02 (1.21–7.54)

0.02

3.33 (1.03–10.79)

0.04

2.08 (079–5.51)

0.14

Factor

975

LITT for Treatment of Glioma

Figure 4. Correlation between tumor volume and the proportion of
tumor covered by the “blue” line (for illustration purposes only the
“blue” line is considered, but the same holds for the “yellow” line also).

prognostic group was marginal (P = 0.16). However, as
shown in Figure 5 the TDT prognostic groups essentially
separate out the patients with low-volume disease who
have a poorer prognosis from those with a better prognosis (P = 0.02).
Analysis of OS produced no statistically significant
results, however, the majority of cases (66%) were still
being followed at the time of the analysis.

Other analysis
Postoperative complications were observed in a few
patients. In general, these complications were subtle and

A. M. Mohammadi et al.

temporary in the majority of cases where they occurred.
Any type of complication was observed after 13/35 LITT
procedures (37%). The most common complication was a
worsening of preoperative neurological deficit (usually
motor) in seven (20%) cases. In five (14%) cases, the new
deficit resolved within a few days; however, the new deficit was permanent in two (6%) cases. One patient experienced new seizure, one patient had postoperative
hyponatremia and one patient developed bilateral deep
vein thrombosis (DVT). Infection was observed in two
(6%) cases, one was superficial wound infection in an old
patient with history of prior radiation and the other one
was ventriculitis.
A small amount of blood products seen within the area
of lasing on neuroimaging after LITT treatment was
observed in more than half of the patients. This was
deemed to be hemorrhagic necrosis that was consistent
and appropriate for the case. Distinct from this typical
treatment response, in three (8%) cases the amount of
hemorrhage was characterized as a moderate to large
intra-cerebral hemorrhage (ICH) compared with the initial tumor size. One of these hemorrhages occurred in a
patient with multiple other complications—intraventricular hemorrhage from surgery, obstructive hydrocephalus
resulting from the hemorrhage, systemic infection unrelated to the procedure itself, and ultimately mortality
when the patient’s family chose withdrawal of care. No
surgical evacuation was performed for any of these cases
of ICH due to the deep location of the initial tumors and
subsequent hemorrhages. All three of the patients who
developed large ICHs harbored newly diagnosed GBM
and one of them underwent biopsy on the same day as
the LITT.

Figure 5. NeuroBlate prognostic groups and tumor volume.
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Discussion
Despite being used for more than two decades, there is
limited published data regarding clinical outcomes from
LITT treatment for high-grade glioma patients. The largest series previously published was by Schwarzmaier
et al. He reported on the OS results from LITT in 16
patients with recurrent GBM. The reported median
survival for these patients was 6.9 months after LITT
and was relatively better than the historical control for
recurrent GBM patients at that time. No permanent neurological deficit or mortality was reported in that series
[14, 29]. The second largest series of LITT in high-grade
glioma was published by Sloan and colleagues. This
series was a phase-I, IDE managed study to evaluate
safety of the NeuroBlate System in 10 patients with
recurrent GBM. Median OS was 10.5 months after the
LITT procedure and no mortality was related to the
procedure [13]. Beyond the two previously mentioned
studies, there are a few other case reports and small case
series (less than 10 patients each) with less efficient irradiation doses (<6 W) [17, 19, 25, 30]. Interestingly, none
of the prior studies have published data regarding the
PFS of the patients.
We evaluated 24 GBM and 10 anaplastic glioma
patients who had undergone LITT as an upfront (16
cases) or salvage treatment (19 cases) for their tumors.
Median tumor coverage by the blue and yellow TDT lines
was 91% and 98%, respectively. Similarly, median tumor
volumes missed by the blue and yellow TDT lines were
0.66 and 0.19 cm3. Based on subsequent statistical analysis, a combination of residual tumor volume missed by
the yellow TDT line <0.05 cm3 plus additional residual
tumor volume missed by blue TDT line <1.5 cm3 was
considered as the TDT-line coverage prognostic factor for
PFS (P = 0.02). In a one-by-one comparison of the TDTline prognostic groups with all of the other potential
prognostic factors, the effect of the TDT-line prognostic
groups remains statistically significant regardless of the
factor considered, with the exception of tumor volume.
However, in recursive partitioning analysis, at least for
the tumors with a volume smaller than 10 cm3, the TDTline prognostic group can differentiate between patients
with a better or worse prognosis for PFS (P = 0.02).
There are no data in the literature regarding the role of
the extent of tumor coverage by the LITT-induced hyperthermic field on outcome for high-grade glioma patients.
However, the neurosurgical literature does contain data
regarding the role of the extent of open surgical resection
on improving outcomes for patients with high-grade gliomas [31]. Most of these studies focused on OS rather
than PFS [6–8, 10]. Jeremic et al. [32] in a review of 86
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patients with newly diagnosed GBM showed surgical
resection versus biopsy has a better outcome in terms of
time to progression (33 vs. 21 weeks). Keles and coworkers also reported a better time to progression with
increase in the extent of resection in a volumetric analysis
of 92 GBM patients [33]. Ushio and colleagues reviewed
105 consecutive GBM patients and showed better PFS for
patients after complete resection (10 months) compared
to partial resection (5 months) and compared to biopsy
(3.6 months) [34]. Finally, in another report Keles analyzed 102 AA patients and showed that the volume of
residual tumor identified on the postoperative T2 MRI
sequence has an impact on time to progression of these
tumors [9].
In this multicenter study, which is the largest series
reported regarding the LITT procedure, we report our
experience using the NeuroBlate System for the treatment
of high-grade glioma patients with a primary focus on
PFS using precise volumetric analysis. As was shown
above, near-complete coverage of the tumor by the TDT
lines has an impact on enhancing PFS for these patients.
A brief review of the existing literature regarding the role
of “extent of resection” from open surgical treatment in
high-grade gliomas suggests that the same value of
“extent of surgical resection” in PFS can be achieved by
the “extent of ablation” by the hyperthermic field in the
LITT procedure. Hence, the cytoreductive effect of hyperthermia can be considered as equivalent to surgical debulking.

Limitations
There are several limitations to this study. First, selection
bias is an inherent risk for nonrandomized retrospective
studies and our study is not an exception. However, every
effort was made to try to include all consecutive cases
with pathological diagnosis of high-grade glioma which
were treated with LITT during the study period at all
three centers. Second, despite being a multicenter study,
the number of patients is still small, and as a result the
study conclusions must be interpreted carefully. Third,
because of the short median follow-up period and small
number of patients we were not able to determine the
effect of TDT-line coverage on OS. Finally, in future
reports with larger numbers of patients, inclusion criteria
should be limited to only one pathologic tumor type
(GBM or AO or AA) with additional consideration of the
genetic and micromolecular features of each patient’s
tumor (e.g., IDH1, MGMT promoter methylation, etc.),
especially for OS analysis. Similarly, separate analyses
should be done for patients treated with upfront versus
salvage procedures.
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Conclusion
Laser interstitial thermal therapy has been shown to have
promising results as a safe and effective treatment modality for high-grade glioma patients in conjunction with
standard medical and radiation therapies. The prognostic
role of the coverage of tumor volume by the hyperthermic field could be considered analogous to the concept of
“extent of resection” in surgical treatment of high-grade
gliomas. Further prospective studies are in preparation to
confirm the effectiveness of LITT for these challenging
tumors.
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